ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . Wor.Bul.Pub.Helt. [Internet]. 2022 Jul. 11 [cited 2026 Apr. 18];12:66-9. Available from: https://www.scholarexpress.net/index.php/wbph/article/view/1135